Viewing Study NCT00386802


Ignite Creation Date: 2025-12-25 @ 3:47 AM
Ignite Modification Date: 2025-12-26 @ 2:34 AM
Study NCT ID: NCT00386802
Status: COMPLETED
Last Update Posted: 2009-09-18
First Post: 2006-10-11
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Antifungal Use in Oncohematological Neutropenic Patients
Sponsor: PETHEMA Foundation
Organization:

Study Overview

Official Title: ANTIVORIFUNGOL:Strategy of Antifungal Use in Oncohematological Neutropenic Patients. Use of Voriconazole as Early Treatment.
Status: COMPLETED
Status Verified Date: 2009-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Primary purpose: Frequency of use of broad-spectrum antifungals in the episode of neutropenia.

Secondary purposes:To determine the safety and toxicity measure by:

1. Frequency of Invader Fungal Infection.
2. Frequency of global use of broad-spectrum antifungals as amphotericine, itraconazole, voriconazole, caspofungin, terbinafine, during the period of study.
3. Mortality
4. Development of nephrotoxicity
5. Use of galactomannan in this clinical context
6. Time of administration of empirical antifungal therapy of broad-spectrum.
Detailed Description: Clinical trial with a pharmaceutical speciality in the conditions of authorized use

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
ANTIVORIFUNGOL None None View